<DOC>
	<DOCNO>NCT01588951</DOCNO>
	<brief_summary>The primary objective trial compare two-year relapse-free survival ( RFS ) patient acute myeloid leukemia ( AML ) , presume high risk relapse due presence leukemia stem cell ( LSCs ) bone marrow first complete remission ( CR1 ) , receive either standard cytarabine-based chemotherapy allogeneic stem cell transplantation ( SCT ) .</brief_summary>
	<brief_title>Consolidation Therapy Acute Myeloid Leukemia Guided Leukemia Stem Cell Behavior</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Age great equal 18 year 2 . Able give inform consent 3 . New diagnosis AML , APL poorrisk AML , define section 3.2 Exclusion criterion : 1 . Has already bone marrow biopsy aspirate ass remission status induction therapy 2 . Any debilitate medical psychiatric illness would preclude ability give inform consent receive optimal treatment followup 3 . Pregnancy : Women childbearing potential Î² HCG+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>